E Fund Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

E Fund Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-11,196	Closed	-$430K	–	327
2023 Q2	$430K	Buy	11,196 +907	+9%	+$23.3K	0.03%	149
2023 Q1	$238K	Buy	10,289 +1,172	+13%	+$27.9K	0.02%	266
2022 Q4	$239K	Buy	+9,117	New	+$202K	0.02%	270

E Fund Management's KDNY Position: Q3 2023 in Review

E Fund Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 11,196 shares — an estimated $430K sold.

E Fund Management first reported a position in KDNY in Q4 2022 and held it in 3 quarters. The position peaked at $430K in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

E Fund Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
E Fund Management sold 11,196 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $430K.
E Fund Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2022 and held it in 3 quarters.
E Fund Management's Chinook Therapeutics, Inc. Common Stock position peaked at $430K in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on E Fund Management's 13F filing for Q3 2023, filed 13 Nov 2023.